• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    12/13/21 4:30:52 PM ET
    $THMA
    Finance
    Get the next $THMA alert in real time by email
    SC 13G 1 d270354dsc13g.htm SC 13G SC 13G

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.    )*

     

     

    Pear Therapeutics, Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    704723105

    (CUSIP Number)

    December 3, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 704723105    Schedule 13G    Page 1 of 9

     

       1   

    Names of Reporting Persons

     

    SB Global Advisers Limited

       2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

       3  

    SEC Use Only

     

       4  

    Citizenship or Place of Organization

     

    England and Wales

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person With

        5     

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    12,100,078

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    12,100,078

       9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,100,078

     10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

     11  

    Percent of Class Represented by Amount in Row 9

     

    8.8%

     12  

    Type of Reporting Person

     

    CO


    CUSIP No. 704723105    Schedule 13G    Page 2 of 9

     

       1   

    Names of Reporting Persons

     

    SoftBank Vision Fund II-2 L.P.

       2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

       3  

    SEC Use Only

     

       4  

    Citizenship or Place of Organization

     

    Jersey

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person With

        5     

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    12,100,078

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    12,100,078

       9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,100,078

     10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

     11  

    Percent of Class Represented by Amount in Row 9

     

    8.8%

     12  

    Type of Reporting Person

     

    PN


    CUSIP No. 704723105    Schedule 13G    Page 3 of 9

     

       1   

    Names of Reporting Persons

     

    SVF II AIV (DE) LLC

       2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

       3  

    SEC Use Only

     

       4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person With

        5     

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    12,100,078

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    12,100,078

       9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,100,078

     10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

     11  

    Percent of Class Represented by Amount in Row 9

     

    8.8%

     12  

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 704723105    Schedule 13G    Page 4 of 9

     

       1   

    Names of Reporting Persons

     

    SVF II Cobbler (DE) LLC

       2  

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

       3  

    SEC Use Only

     

       4  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person With

        5     

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    12,100,078

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    12,100,078

       9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,100,078

     10  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

     11  

    Percent of Class Represented by Amount in Row 9

     

    8.8%

     12  

    Type of Reporting Person

     

    OO (Limited Liability Company)


    CUSIP No. 704723105    Schedule 13G    Page 5 of 9

     

    ITEM 1.

    (a) Name of Issuer:

    Pear Therapeutics, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    200 State Street, 13th Floor, Boston, MA 02109.

     

    ITEM 2.

    (a) Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    SB Global Advisers Limited

    SoftBank Vision Fund II-2 L.P.

    SVF II AIV (DE) LLC

    SVF II Cobbler (DE) LLC

     

      (b)

    Address or Principal Business Office:

    The principal business address for SB Global Advisers Limited is 69 Grosvenor Street, London W1K 3JP, United Kingdom. The principal business address for SoftBank Vision Fund II-2 L.P. is Crestbridge Limited, 47 Esplanade, St. Helier, Jersey, JE1 0BD. The principal business address for each of SVF II AIV (DE) LLC and SVF II Cobbler (DE) LLC is 251 Little Falls Drive, Wilmington, DE 19808.

     

      (c)

    Citizenship of each Reporting Person is:

    SB Global Advisers Limited is organized under the laws of England and Wales. SoftBank Vision Fund II-2 L.P. is organized under the laws of Jersey. Each of SVF II AIV (DE) LLC and SVF II Cobbler (DE) LLC is organized under the laws of the State of Delaware.

     

      (d)

    Title of Class of Securities:

    Class A common stock, par value $0.0001 per share (“Class A Common Stock”).

     

      (e)

    CUSIP Number:

    704723105

     

    ITEM 3.

    Not applicable.


    CUSIP No. 704723105    Schedule 13G    Page 6 of 9

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of shares of Class A Common Stock of the Issuer based upon 137,799,218 shares of Class A Common Stock outstanding as of December 3, 2021.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole
    power
    to vote
    or to
    direct
    the vote:
         Shared
    power to
    vote or to
    direct
    the vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    SB Global Advisers Limited

         12,100,078        8.8 %      0        12,100,078        0        12,100,078  

    SoftBank Vision Fund II-2 L.P.

         12,100,078        8.8 %      0        12,100,078        0        12,100,078  

    SVF II AIV (DE) LLC

         12,100,078        8.8 %      0        12,100,078        0        12,100,078  

    SVF II Cobbler (DE) LLC

         12,100,078        8.8 %      0        12,100,078        0        12,100,078  

    SVF II Cobbler (DE) LLC is the record holder of 12,100,078 shares of Class A Common Stock.

    SoftBank Vision Fund II-2 L.P. is the managing member of SVF II AIV (DE) LLC, which is the sole member of SVF II Cobbler (DE) LLC. SB Global Advisers Limited has been appointed as manager and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund II-2 L.P.’s investments, including as held by SVF II Cobbler (DE) LLC. As a result of these relationships, each of these entities may be deemed to share beneficial ownership of the securities held of record by SVF II Cobbler (DE) LLC.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 704723105    Schedule 13G    Page 7 of 9

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 704723105    Schedule 13G    Page 8 of 9

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: December 13, 2021

     

    SB Global Advisers Limited
    By:  

    /s/ Spencer Collins

    Name:   Spencer Collins
    Title:   Director
    SoftBank Vision Fund II-2 L.P.
    By: SB Global Advisers Limited, its Manager
    By:  

    /s/ Spencer Collins

    Name:   Spencer Collins
    Title:  

    Director

    SVF II AIV (DE) LLC
    By:  

    /s/ Ian McLean

    Name:   Ian McLean
    Title:   Director
    SVF II Cobbler (DE) LLC
    By:  

    /s/ Ian McLean

    Name:   Ian McLean
    Title:   Director

     


    CUSIP No. 704723105    Schedule 13G    Page 9 of 9

     

    LIST OF EXHIBITS

     

    Exhibit No.   

    Description

    99    Joint Filing Agreement.
    Get the next $THMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THMA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Thimble Point Acquisition Corp.

    25-NSE - Thimble Point Acquisition Corp. (0001835567) (Subject)

    12/3/21 4:02:15 PM ET
    $THMA
    Finance

    SEC Form 425 filed by Thimble Point Acquisition Corp.

    425 - Thimble Point Acquisition Corp. (0001835567) (Subject)

    11/30/21 4:42:53 PM ET
    $THMA
    Finance

    Thimble Point Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Thimble Point Acquisition Corp. (0001835567) (Filer)

    11/30/21 4:38:59 PM ET
    $THMA
    Finance

    $THMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider 5am Partners Iv, Llc claimed ownership of 18,631,771 shares

    3 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/13/21 4:26:37 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Bauerlein Alison

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:47:18 PM ET
    $THMA
    Finance

    SEC Form 4 filed by Reddy Kirthiga

    4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

    12/10/21 4:46:17 PM ET
    $THMA
    Finance

    $THMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company

    Publicly traded company called Pear Therapeutics, Inc. to begin trading on Nasdaq under ticker symbol "PEAR" starting December 6, 2021 Total expected gross proceeds from transaction totaling approximately $175 million Pear Therapeutics, Inc. ("Pear Therapeutics"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced today the completion of its business combination with Thimble Point Acquisition Corp. ("Thimble Point") (NASDAQ:THMA), a special purpose acquisition company ("SPAC"). The publicly traded company will be known as Pear Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol "

    12/3/21 4:12:00 PM ET
    $THMA
    Finance

    Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 8:50 a.m. ET. A live audio webcast can be accessed by clicking here and will be made available on Pear's website at www.peartherapeutics.com. A replay will be available for approximately 30 days following the live presentation. About Pear Therapeutics Pear Therapeutics is the leader in prescription digital therapeutics, or PD

    11/23/21 8:00:00 AM ET
    $THMA
    Finance

    Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

    Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder (AUD). reSET-A potentially expands Pear's addiction franchise, which includes FDA-authorized products to treat substance use disorder (SUD) and opioid use disorder (OUD). This is the second such Breakthrough Device Designation received by Pear, following the designation awarded for reSET-O®, the first ever for a PDT, which was for the treatment

    11/22/21 8:00:00 AM ET
    $THMA
    Finance

    $THMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Thimble Point Acquisition Corp.

    SC 13G - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:30:52 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:57 PM ET
    $THMA
    Finance

    SEC Form SC 13D filed by Thimble Point Acquisition Corp.

    SC 13D - Pear Therapeutics, Inc. (0001835567) (Subject)

    12/13/21 4:16:15 PM ET
    $THMA
    Finance